Рак молочной железы

Top 9 Takeaways From ASCO’s 2026 Breast Cancer Surveillance Update

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer - Yahoo Finance

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Yahoo Finance

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer - PR Newswire

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer PR Newswire

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer - Yahoo Finance

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Yahoo Finance

Demographics, Tumor Biology and Treatment Outcomes of Male Breast Cancer Patients From a Tertiary Cancer Center in North India: A Real-World Study - Cureus

Demographics, Tumor Biology and Treatment Outcomes of Male Breast Cancer Patients From a Tertiary Cancer Center in North India: A Real-World Study Cureus

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer - Business Wire

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer Business Wire

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance - The American Journal of Managed Care

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance The American Journal of Managed Care

ASPEN-09-03 Trial Aims to Build the Case for Evorpacept in Post–T-DXd HER2+ Breast Cancer - OncLive

ASPEN-09-03 Trial Aims to Build the Case for Evorpacept in Post–T-DXd HER2+ Breast Cancer OncLive

Treatment Options When Metastatic Triple-Negative Breast Cancer Becomes Unresponsive to Chemotherapy - Everyday Health

Treatment Options When Metastatic Triple-Negative Breast Cancer Becomes Unresponsive to Chemotherapy Everyday Health

Peter MacCallum Cancer Centre Highlights AI Advances in Breast Cancer - Oncodaily

Peter MacCallum Cancer Centre Highlights AI Advances in Breast Cancer Oncodaily

A 'one-two punch' against aggressive breast cancer could offer an alternative to chemotherapy

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

An RNA molecule contributes to therapy resistance of triple negative breast cancer

Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Chemotherapy before or after surgery remains the standard treatment regimen for stage I–III TNBC. Only a small portion of patients can benefit from targeted therapy with PARP inhibitors because of BRCA mutations. However, resistance to…

Could Letrozole, a Breast Cancer Drug, Help Treat Uterine Fibroids? - Black Doctor

Could Letrozole, a Breast Cancer Drug, Help Treat Uterine Fibroids? Black Doctor

Olubukola Ayodele: Global Oncology Lessons From Breast Cancer Care in China - Oncodaily

Olubukola Ayodele: Global Oncology Lessons From Breast Cancer Care in China Oncodaily

An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan

An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone Stock Titan